- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05445050
mULM to Support Breast Cancer Diagnosis and Therapy
Development of Motion-Model Ultrasound Localization Microscopy to Support Breast Cancer Diagnosis and Therapy Monitoring in Patients
Study Overview
Status
Conditions
Detailed Description
This study on the clinical translation of the super-resolution ultrasound imaging technique motion-model ultrasound localization microscopy (mULM) is composed of three parts. First, an ultrasound scan protocol will be developed by providing patients with primary breast carcinoma with an ultrasound scan to assess the size, location, and structure of the tumor. Images in the form of B-mode ultrasound, elastography, and contrast ultrasound will be obtained, and mini-movies of the CEUS examinations will be evaluated in a post-processing step. There, individual microbubbles of the ultrasound contrast agent will be identified and tracked to reconstruct the microvasculature of the tumor lesions. Participants will each receive 2 different doses of the clinically approved ultrasound contrast agent SonoVue®. The morphological and functional parameters obtained through the post-processing with the mULM algorithm are then analyzed and subsequently validated with histological examinations. Finally, the ultrasound examination protocol will be optimized and the corresponding dosage of the ultrasound contrast agent determined.
The examination protocol established in the first section will subsequently be applied to patients with primary breast carcinoma receiving neoadjuvant chemotherapy. Contrast-enhanced ultrasonography will be performed at three time points during the chemotherapy cycles and will be performed to assess tumor perfusion through application of the mULM-algorithm. The dosage of contrast agent is based on the dosage found in the previous part of the study. The CEUS examination is followed by the infusion of the chemotherapeutic agent. After completion of neoadjuvant chemotherapy, surgical resection of the tumor and microscopic examination of the tissue are performed according to guidelines.
In the final part of the study, patients with suspected breast tumor lesions are examined. They will first receive non-contrast-enhanced diagnostic ultrasound (B-mode and elastography). A contrast-enhanced ultrasound examination is performed on the largest lesion. To further develop the mULM methodology, this is performed as both 2D and 3D acquisition. The dosage of the contrast agent examination is again based on the optimal dosage found in the first study part. This ultrasound procedure is followed by guideline-guided biopsy for histologic clarification of the tumors, assessing dignity, hormone receptor as well as and HER2/neu status, proliferation rate, and vessel density.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Elmar Stickeler, Prof Dr. med
- Phone Number: +492418088400
- Email: estickeler@ukaachen.de
Study Contact Backup
- Name: Fabian Kiessling, Prof Dr. med
- Phone Number: +49 241 80 80117
- Email: fkiessling@ukaachen.de
Study Locations
-
-
NRW
-
Aachen, NRW, Germany, 52074
- Recruiting
- Department of Gynecology and Obstetrics Universitätsklinikum Aachen, AöR
-
Contact:
- Elmar Stickeler
- Phone Number: +492418088400
- Email: estickeler@ukaachen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- written informed consent
- age ≥ 18 yrs
- histologically confirmed primary breast cancer including all intrinsic subtypes (study parts A and B)
- highly suspected primary breast cancer (study part C)
- treatment with neoadjuvant chemotherapy (study part B)
- persons who are legally competent and mentally able to follow the instructions of the study team
Exclusion Criteria:
- younger than 18 years
- hypersensitivity / allergy to sulfur hexafluoride, Macrogol 4000, distearoylphosphatidylcholine, dipalmitoylphosphatidylglycerol-sodium, palmitic acid
- right-left shunt,
- signs of cardiovascular instability
- acute endocarditis
- artificial heart valves
- acute systemic inflammation and/or sepsis
- overactive coagulation status and/or recent thromboembolic events
- end stage of liver and kidney diseases
- severe pulmonary hypertension (pulmonary arterial pressure > 90 mmHg)
- uncontrolled systemic hypertension
- acute respiratory distress syndrome
- pregnancy
- commitment of the patient to any resident institution by order of any court or authority
- expectation of missing compliance
- alcohol or drug abuse
- patients who are in a relationship of dependence or in a working relationship to the sponsor, the investigator or his representative
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: clinical application of mULM to support breast cancer diagnosis and therapy
The study arm includes three parts A, B and C. In part A, the scan protocol, including the injection of the clinically approved contrast agent SonoVue® and the data acquisition time range, is optimized based on the mULM measurements of participants with primary breast cancer. The following part B consists of 2D-mULM measurements applied to triple-negative breast cancer patients throughout their neoadjuvant chemotherapy cycles with the aim to evaluate to which degree 2D-mULM allows for an assessment of the tumor response during therapy. In the last part C, participants with neoplasms of uncertain dignity will be investigated by 2D- and 3D-mULM measurements and the accuracy of differentiation between the lesions assessed. |
Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative blood volume
Time Frame: Study Part A & C: approximately 1 day before surgical removal of tumor
|
Relative blood volume in % - describes the degree of vascularization - measured with mULM
|
Study Part A & C: approximately 1 day before surgical removal of tumor
|
Blood flow
Time Frame: Study Part A & C: approximately 1 day before surgical removal of tumor
|
Blood flow in mm/s - measured with mULM
|
Study Part A & C: approximately 1 day before surgical removal of tumor
|
Change of relative blood volume
Time Frame: Study Part B: at the beginning of (approximately 1 hour before) first, second and fourth cycle of neoadjuvant chemotherapeutic treatment (each cycle is 14 days)
|
Change of relative blood volume in %
|
Study Part B: at the beginning of (approximately 1 hour before) first, second and fourth cycle of neoadjuvant chemotherapeutic treatment (each cycle is 14 days)
|
Change of blood flow
Time Frame: Study Part B: at the beginning of (approximately 1 hour before) first, second and fourth cycle of neoadjuvant chemotherapeutic treatment (each cycle is 14 days)
|
Change of blood flow in mm/s
|
Study Part B: at the beginning of (approximately 1 hour before) first, second and fourth cycle of neoadjuvant chemotherapeutic treatment (each cycle is 14 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of tumor size
Time Frame: Study Part B: at the beginning of (approximately 1 hour before) first, second and fourth cycle of neoadjuvant chemotherapeutic treatment (each cycle is 14 days)
|
Change of tumor size determined based on ultrasound B-mode imaging
|
Study Part B: at the beginning of (approximately 1 hour before) first, second and fourth cycle of neoadjuvant chemotherapeutic treatment (each cycle is 14 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elmar Stickeler, Prof Dr. med, RWTH Aachen University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 351-19
- DRKS00023954 (Other Identifier: DRKS (German Clinical Trials Register))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Breast Cancer
-
Queen Mary University of LondonAstellas Pharma IncUnknownPrimary Breast Cancer ER+ve | Primary Breast Cancer AR+ve TNBNGermany, United Kingdom, Spain, United States, Ireland
-
University Health Network, TorontoCompletedBreast Cancer Invasive Nos | Primary Invasive Breast CancerCanada
-
Tao OUYANGPeking University First Hospital; 307 Hospital of PLA; Peking University People... and other collaboratorsActive, not recruiting
-
German Breast GroupCompleted
-
Kliniken Essen-MitteRecruitingPrimary Breast CancerGermany
-
Fudan UniversityChinese Anti-Cancer AssociationCompleted
-
Fudan UniversityCompleted
-
Klinikum WeissenfelsCompletedPrimary Breast CancerGermany
-
German Breast GroupGerman Adjuvant Breast Cancer GroupCompleted
-
Tomsk National Research Medical Center of the Russian...RecruitingPrimary Breast CancerRussian Federation
Clinical Trials on Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)
-
University of NottinghamCompletedHealthy VolunteersUnited Kingdom
-
Centre Hospitalier Universitaire VaudoisUniversity Hospital, GenevaCompletedChronic Renal Failure | Healthy ControlsSwitzerland
-
University of NottinghamUnknownHealthy VolunteersUnited Kingdom